Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation

2 september 2026 uppdaterad av: Servier

A Phase 1/2, Dose Optimization and Dose Expansion, Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Menin Inhibitor S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Patients With Relapsed or Refractory Acute Myeloid Leukemia With NPM1c Mutation

The objective of this study is to establish the efficacy, safety, and tolerability of S243249 and to establish the recommended phase 2 dose (RP2D) of S243249 monotherapy in participants with relapsed/refractory (R/R) acute leukemia with select mutations. Phase 1 dose optimization will determine the RP2D to be used in Phase 2 dose expansion. The study will include a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up period and a long-term follow-up period. Participants may undergo blood tests, electrocardiogram (ECG), bone marrow aspirations, vital sign checks, questionnaires, and physical exams.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

80

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Aged ≥ 18 years old.
  • Negative serum pregnancy (β-hCG) test in women of childbearing potential at screening
  • Cytomorphology-confirmed diagnosis of R/R acute leukemia (including AML, ALL, and mixed lineage leukemia) according to the WHO criteria in 2022. R/R acute leukemia must meet at least one of the following conditions:
  • Primary refractory disease, defined as non-response to 2 courses of standard induction therapy.
  • R/R disease, defined as > 5% blasts on bone marrow aspirate (BMA) / bone marrow biopsy (BMB) after completing prior therapy.
  • Relapse after allogeneic hematopoietic stem cell transplantation (HSCT), autologous HSCT, or immunotherapy such as chimeric antigen receptor T cell therapy (CAR-T) and T cell engager (TCE).
  • Participants with secondary AML or AML transformed from myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), etc., can be included in the study, if they meet the above criteria after the disease has transformed into AML.
  • Confirmation of KMT2At, NUP98t, or NPM1c mutation using next generation sequencing (NGS), fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR) based test in an accredited local or central lab within 28 days before start of treatment.
  • Peripheral blood white blood cell (WBC) count ≤ 25 mm3 (hydroxyurea, steroids, or vincristine to reduce peripheral WBC count is permitted).
  • Participants will be at least 2 weeks from prior therapy (except hydroxyurea, vincristine, or steroids and prespecified prephase therapy) and recovered from nadir to no worse than Grade 1 nonhematological toxicity from the prior treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  • Adequate electrolytes, liver, kidney, and cardiac function
  • Sexually active male or female participants of childbearing potential must agree to use 2 medically accepted forms of effective contraception, e.g., oral, parenteral, or implanted contraceptives; intrauterine devices; and barrier methods with spermicides, during the study and for 3 or 6 months after the final administration of investigational medicinal product (IMP), in males and females respectively. Egg donation is not allowed during the study or within 6 months of the last dose of S243249.
  • Male participants with women of childbearing potential (WOCBP) partners must use a condom during the study and for at least 3 months after the final administration of IMP.

Exclusion Criteria:

  • Active central nervous system (CNS) leukemia (including imaging abnormalities and cerebrospinal fluid (CSF) smear or flow cytometry indicating leukemia cells)).
  • Active disseminated intravascular coagulation (DIC).
  • Active uncontrolled infection (prophylaxis because of absolute neutrophil count [ANC] is excepted).
  • Diagnosis of acute promyelocytic leukemia (APL, M3).
  • Corrected QT interval calculated by Fridericia (QTcF) > 450 msec on screening ECG.
  • Participants with an increased pro-arrhythmic risk such as those with congenital long QT syndrome.
  • Uncontrolled or severe cardiovascular disease, , within 12 months.
  • Uncontrolled serious arrhythmias.
  • Clinically significant pericardial disease.
  • History of other malignancy within the past 5 years.
  • Participants who receive autologous hematopoietic stem cell transplantation (ASCT) or CAR-T therapy within 60 days of the first dose of S243249 or have not yet recovered from toxicity related to ASCT or CAR-T therapy.
  • Participants who receive allogeneic HSCT within 100 days of the first dose of S243249, still have active acute or chronic graft versus host disease (GVHD), or still require immune-modulating therapy.
  • Have an active infection of hepatitis B or hepatitis C.
  • Have advanced liver disease or cirrhosis.
  • Uncontrolled human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome related illness.
  • Pregnant and/or breast-feeding (lactating) women.
  • Participant has received anti-leukemia treatment, including chemotherapy, radiation therapy, targeted small molecule agents, biologic agents, immunotherapy, or any other investigational therapy (excluding hydroxyurea, or vincristine for cytoreduction) within 2 weeks prior to the first dose of S243249.
  • Previous treatment targeting menin, dose optimization phase only.
  • Any concomitant participation in another therapeutic clinical trial is prohibited. Any participation in another nontherapeutic clinical trial could be approved by the medical monitor.
  • Participants taking medications known to prolong the QT/QTc interval (with the exception of necessary azole antifungals).
  • Ongoing toxicity from prior anti-leukemia therapy that has not resolved to Grade 1 7 days prior to the first dose of S243249 has to be approved by the medical monitor.
  • Uncontrolled active infection
  • Known allergy or hypersensitivity to menin inhibitors or any component of S243249.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Phase 1 Dose Optimization: Cohort 1
For participants without strong CYP3A4 inhibitors
Taken twice daily by mouth
Experimentell: Phase 1 Dose Optimization: Cohort 2
For participants without strong CYP3A4 inhibitors
Taken twice daily by mouth
Experimentell: Phase 1 Dose Optimization: Cohort 3
For participants with strong CYP3A4 inhibitors
Taken twice daily by mouth
Experimentell: Phase 1 Dose Optimization: Cohort 4
For participants with strong CYP3A4 inhibitors
Taken twice daily by mouth

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Incidence of Adverse Events (AEs)
Tidsram: Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Severity of AEs
Tidsram: Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of changes in laboratory values
Tidsram: Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of changes in electrocardiogram (ECG)
Tidsram: Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of changes in vital signs
Tidsram: Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to dose interruption
Tidsram: Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to dose modification
Tidsram: Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to dose delays
Tidsram: Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to permanent treatment discontinuation
Tidsram: Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Complete remission (CR) + Complete remission with partial recovery of hematology (CRh) rate
Tidsram: Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall response rate (ORR)
Tidsram: Through Long-term Follow-up (Approximately 5 years)
CR + CRh + Complete remission with incomplete hematological recovery (CRi) + Morphologically leukemic state (MLFS) + Partial remission (PR)
Through Long-term Follow-up (Approximately 5 years)
Composite complete remission (CRc) rate
Tidsram: Through Long-term Follow-up (Approximately 5 years)
CRc is CR + CRh + CRi
Through Long-term Follow-up (Approximately 5 years)
CR rate
Tidsram: Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Rate of CR/CRh Minimal residual disease (MRD) negativity
Tidsram: Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Duration of response (DOR)
Tidsram: Through Long-term Follow-up (Approximately 5 years)
Measured from the date of first achievement of CR/CRh, CR, CR/CRh MRD negativity, CRc and ORR until hematologic relapse or death from any cause
Through Long-term Follow-up (Approximately 5 years)
Time to response (TTR)
Tidsram: Through Long-term Follow-up (Approximately 5 years)
Measured from the date of first dose administration until the first achievement of CR/CRh, CR, CR/CRh MRD negativity, CRc and ORR
Through Long-term Follow-up (Approximately 5 years)
Transfusion independence 56 days (TI-56)
Tidsram: Through Long-term Follow-up (Approximately 5 years)
The absence of red blood cells and platelet transfusions lasting for 56 consecutive days during which the patient is either on Investigational medicinal product (IMP) or following discontinuation from IMP but before the start of new therapy.
Through Long-term Follow-up (Approximately 5 years)
Transfusion independence 112 days (TI-112)
Tidsram: Through Long-term Follow-up (Approximately 5 years)
The absence of red blood cells and platelet transfusions lasting for 112 consecutive days during which the patient is either on IMP or following discontinuation from IMP but before the start of new therapy.
Through Long-term Follow-up (Approximately 5 years)
Event free survival (EFS)
Tidsram: Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Cumulative relapse rate (CIR)
Tidsram: Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Cumulative mortality (CID)
Tidsram: Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Overall survival (OS)
Tidsram: Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Quality of Life (QoL) measured via EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L)
Tidsram: Through Safety Follow-up (Approximately 3 years)
EQ-5D-5L scores range from 0-5 with 5 representing the best QoL.
Through Safety Follow-up (Approximately 3 years)
QoL measured via Hematological malignancy specific patient-reported outcome (HM-PRO)
Tidsram: Through Safety Follow-up (Approximately 3 years)
HM-PRO Part A scores range from 0 to 48 and Part B scores from 0 to 36, with a higher score representing the largest impact on quality of life.
Through Safety Follow-up (Approximately 3 years)
Health economic outcomes measured via EQ-5D-5L
Tidsram: Through Safety Follow-up (Approximately 3 years)
EQ-5D-5L scores range from 0-1 with 1 representing the best health economic outcomes.
Through Safety Follow-up (Approximately 3 years)
Health economic outcomes measured via HM-PRO
Tidsram: Through Safety Follow-up (Approximately 3 years)
HM-PRO scores range from 0 to 48, with a higher score representing the largest impact on health economic outcomes.
Through Safety Follow-up (Approximately 3 years)
Ability to proceed to hematopoietic stem cell transplantation (HSCT) as assessed by the investigator
Tidsram: Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Plasma concentration of S243249 and relevant metabolites
Tidsram: Through Cycle 6 Day 1 (each cycle is 28 days)
Plasma samples will be analyzed to determine concentrations of S243249 and relevant metabolites
Through Cycle 6 Day 1 (each cycle is 28 days)
Tmax
Tidsram: Through Cycle 6 Day 1 (each cycle is 28 days)
Time to observed maximum plasma concentration of S243249 and relevant metabolites
Through Cycle 6 Day 1 (each cycle is 28 days)
Cmax
Tidsram: Through Cycle 6 Day 1 (each cycle is 28 days)
Maximum plasma concentration of S243249 and relevant metabolites
Through Cycle 6 Day 1 (each cycle is 28 days)
AUC0-t
Tidsram: Through Cycle 6 Day 1 (each cycle is 28 days)
Area under the plasma concentration-time curve from time 0 to time t of S243249 and relevant metabolites
Through Cycle 6 Day 1 (each cycle is 28 days)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

20 oktober 2026

Primärt slutförande (Beräknad)

11 augusti 2029

Avslutad studie (Beräknad)

25 augusti 2030

Studieregistreringsdatum

Först inskickad

13 juli 2026

Först inskickad som uppfyllde QC-kriterierna

22 juli 2026

Första postat (Faktisk)

23 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • BN104-102
  • 2025 (U.S.S. NIH-anslag/kontrakt: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
  • 2025-524689-74-00 (Ctis)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.

Access can be requested for all interventional clinical studies:

  • used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
  • where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.

In addition, access can be requested for all interventional clinical studies in patients:

  • sponsored by Servier
  • with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Tidsram för IPD-delning

After Marketing Authorization in EEA or US if the study is used for the approval.

Kriterier för IPD Sharing Access

Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera